Abstract
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Full Text
What is claimed is:
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region.
The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Timeline
Filed
06/12/2026Published
10/01/2026Granted
Not AvailableIPC Codes(12)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 31/337:having four-membered rings, e.g. taxol
A61K 31/517:ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine